CYP17 inhibitors—abiraterone, C17,20-lyase inhibitors and multi-targeting agents | Nature Reviews Urology
CYP17 inhibitors for prostate cancer therapy - ScienceDirect
Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors | Scientific Reports
APExBIO - TOK-001|CYP17 inhibitor and androgen receptor (AR) antagonist|CAS# 851983-85-2
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials | Signal Transduction and Targeted Therapy
Evidence-based capacity of natural cytochrome enzyme inhibitors to increase the effectivity of antineoplastic drugs | SpringerLink
CYP17 inhibitors for prostate cancer therapy - ScienceDirect
Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations | Prostate Cancer and Prostatic Diseases
APExBIO - Abiraterone|Potent CYP17 inhibitor|CAS# 154229-19-3
CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer | British Journal of Cancer
Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses | Arteriosclerosis, Thrombosis, and Vascular Biology
Inhibition of cytochrome P450 3A by acetoxylated analogues of resveratrol in in vitro and in silico models | Scientific Reports
Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001 | Nature
CYP17 inhibitors in prostate cancer: latest evidence and clinical potential - Anitha B. Alex, Sumanta K. Pal, Neeraj Agarwal, 2016
CYP17 inhibition as a hormonal strategy for prostate cancer | Nature Reviews Urology
Frontiers | Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
Drug discovery in advanced prostate cancer: translating biology into therapy | Nature Reviews Drug Discovery
Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer | Scientific Reports
Pharmaceuticals | Free Full-Text | Mechanism of the Dual Activities of Human CYP17A1 and Binding to Anti-Prostate Cancer Drug Abiraterone Revealed by a Novel V366M Mutation Causing 17,20 Lyase Deficiency
Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors | Scientific Reports
Orphan nuclear receptors as regulators of intratumoral androgen biosynthesis in castration-resistant prostate cancer | Oncogene
